MedPath

The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery

Phase 4
Recruiting
Conditions
Postoperative Pain
Interventions
Other: Placebo
Registration Number
NCT06743802
Lead Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Brief Summary

This study aimed to assess the effectiveness of Coenzyme Q10 in preventing both acute and chronic pain following thoracoscopic surgery, with a focus on its potential benefits in reducing the incidence and severity of pain.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
264
Inclusion Criteria
  • Aged 18-75 years;
  • American Society of Anesthesiology (ASA) physical status classification I-III;
  • Scheduled for elective lung resection surgery under thoracoscopy;
  • Voluntarily opting for patient-controlled intravenous analgesia;
  • Willing to participate in this trial after consultation with the patient or their family and signing the informed consent form.
Exclusion Criteria
  • History of previous thoracotomy or thoracoscopic surgery;
  • Patients converted to open thoracotomy intraoperatively;
  • Severe hepatic or renal dysfunction;
  • History of substance abuse;
  • Pregnancy or breastfeeding;
  • History of chronic pain;
  • Use of coenzyme Q10 for more than one month;
  • Allergy to coenzyme Q10;
  • Patients unable to communicate or cooperate.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Coenzyme Q10Coenzyme Q10-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
The incidence of chronic postsurgical painfrom the end of surgery to 3 months after surgery
Secondary Outcome Measures
NameTimeMethod
The incidence of acute postoperative pain with a score ≥4from the end of surgery to 6 hours,12 hours, 24 hours , 48 hours and 72 hours after surgery.

Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score. (NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

The severity of acute postoperative painfrom the end of surgery to 6 hours,12 hours, 24 hours , 48 hours and 72 hours after surgery.

Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

The severity of chronic postsurgical painfrom the end of surgery to 3 months after surgery

Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

The incidence of neuropathic painfrom the end of surgery to 3 months after surgery

The DN4 questionnaire (Douleur Neuropathique 4) was used to evaluate neuropathic pain. The DN4 is a validated diagnostic tool consisting of 10 items, with scores ranging from 0 to 10. A score of 4 or higher indicates the presence of neuropathic pain.

The frequency of postoperative rescue analgesic usefrom the end of surgery to 6 hours,12 hours, 24 hours , 48 hours and 72 hours after surgery.
The dose of analgesic usefrom the end of surgery to 6 hours,12 hours, 24 hours and 48 hours after surgery.
The quality of recovery score at 3 days Postoperativelyfrom the end of surgery to 3 days.

The QoR-15 scale, ranging from 0 to 150 with higher scores indicating better recovery, was used to assess the quality of recovery on postoperative day 3.

Health related quality of life score at 3 months Postoperativelyfrom the end of surgery to 3 months after surgery.

The SF-8 scale, with a scoring range of 0 to 100 where higher scores indicate better physical and mental health, was used to evaluate health-related quality of life at 3 months postoperatively.

Postoperative length of hospital stayfrom end of surgery to about 3 to 7 days after surgery.
The incidence of adverse reactionsFrom admission to 3 month post-discharge

Trial Locations

Locations (1)

Guangyou Duan

🇨🇳

Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath